Last A$0.78 AUD
Change Today +0.02 / 2.63%
Volume 201.3K
IPD On Other Exchanges
Symbol
Exchange
Berlin
OTC US
As of 12:10 AM 12/22/14 All times are local (Market data is delayed by at least 15 minutes).

impedimed ltd (IPD) Snapshot

Open
A$0.77
Previous Close
A$0.76
Day High
A$0.79
Day Low
A$0.77
52 Week High
11/3/14 - A$0.87
52 Week Low
06/12/14 - A$0.17
Market Cap
228.6M
Average Volume 10 Days
381.6K
EPS TTM
A$-0.04
Shares Outstanding
293.0M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMPEDIMED LTD (IPD)

Related News

No related news articles were found.

impedimed ltd (IPD) Related Businessweek News

No Related Businessweek News Found

impedimed ltd (IPD) Details

ImpediMed Limited develops, manufactures, and sells bioimpedance and bioimpedance spectroscopy devices, and consumables for clinicians and allied health professionals in Australia, Canada, Mexico, The United States, and internationally. The company operates through Medical, and Test & Measurement segments. The Medical segment offers non-invasive medical devices for the assessment and monitoring of secondary lymphoedema, general health assessment and weight management, muscle wasting, drug dosing and monitoring, and sports medicine and fitness, as well as body composition and hydration. The Test & Measurement segment supplies power precision testing and measuring equipment. The company offers its products through distributors. ImpediMed Limited was founded in 1999 and is based in Pinkenba, Australia.

30 Employees
Last Reported Date: 08/27/14
Founded in 1999

impedimed ltd (IPD) Top Compensated Officers

Chief Executive Officer and President
Total Annual Compensation: A$571.1K
Chief Financial Officer
Total Annual Compensation: A$282.2K
Vice President of Global Commercialization
Total Annual Compensation: A$313.4K
Vice President of Product Development, Qualit...
Total Annual Compensation: A$267.7K
Vice President of Regulatory, Clinical Affair...
Total Annual Compensation: A$267.7K
Compensation as of Fiscal Year 2014.

impedimed ltd (IPD) Key Developments

ImpediMed Limited, Annual General Meeting, Oct 30, 2014

ImpediMed Limited, Annual General Meeting, Oct 30, 2014., at 14:00 E. Australia Standard Time. Location: Corrs Chambers Westgarth Level 42. Agenda: To consider the annual financial report of the company, together with the directors' report and auditor's report, for the year ended June 30, 2014; to consider remuneration report; to elect directors; to consider to issue shares; and to approve the employee incentive plan.

ImpediMed Appoints Frank A. Vicini as its Chief Medical Officer

ImpediMed announced the appointment of Dr. Frank A. Vicini, MD, FACR as its first Chief Medical Officer. The American Medical Association recently released a new CPT® I code for lymphoedema assessment. As a result, Dr. Vicini has joined ImpediMed to provide oncology expertise and leadership across the company and act as an advisor to future business development and strategy. He will also support ImpediMed's medical education and publication strategies. Dr. Vicini is an internationally-recognized radiation oncologist. He has extensive experience in cancer clinical trial design and implementation. Dr. Vicini has held multiple academic appointments, authored over 200 peer-reviewed articles and been involved in numerous clinical studies focusing on cancer treatment. He is currently the Co- Investigator of the ImpediMed L-Dex international post-approval clinical study and the Principal Investigator of several National Institutes of Health (NIH) trials with the goal of improving therapeutic outcomes for all stages of breast cancer, reducing treatment times and minimizing toxicities of healthy tissues and vital organs.

ImpediMed Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 01:30 PM

ImpediMed Limited Presents at 2014 Bioshares Biotech Summit, Jul-18-2014 01:30 PM. Venue: Rydges Lakeland Resort, Queenstown, New Zealand. Speakers: Richard Carreon, Chief Executive Officer and President.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IPD:AU A$0.78 AUD +0.02

IPD Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IPD.
View Industry Companies
 

Industry Analysis

IPD

Industry Average

Valuation IPD Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 39.5x
Price/Book 11.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 51.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMPEDIMED LTD, please visit www.impedimed.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.